Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

Verrica Reports Strong Q1 2026 YCANTH Demand and Pipeline Progress

Verrica Pharmaceuticals announced its first-quarter 2026 financial results, showcasing significant growth for its commercial product, YCANTH (VP-102), for molluscum contagiosum. Dispensed applicator units for YCANTH reached 15,302, marking a 51.3% year-over-year increase, contributing to U.S. net product revenue of $4.3 million and total revenue of $5.0 million. The company also reported the commercial launch of YCANTH in Japan through its partner Torii Pharmaceutical and substantial progress in its global Phase 3 common warts program, with over 50% enrollment achieved in the COVE-2 trial. Additionally, Verrica is advancing its VP-315 program for basal cell carcinoma, with Phase 2 data slated for presentation at the 2026 SID Annual Meeting.

• YCANTH demonstrated robust commercial growth in Q1 2026, with dispensed applicator units increasing 51.3% year-over-year to 15,302. This strong demand led to U.S. net product revenue of $4.3 million, a 25.4% increase from the prior year. The product also expanded internationally with its commercial launch in Japan by partner Torii Pharmaceutical, marking its first ex-U.S. market.
• Verrica achieved a significant milestone in its global Phase 3 program for common warts, announcing over 50% of current targeted enrollment in the first trial, COVE-2. The company anticipates initiating the second Phase 3 trial, COVE-3, in mid-2026, with sites in both the U.S. and Japan, aiming to address an estimated 22 million patients in the U.S. alone.
• The company provided an update on its novel oncolytic peptide, VP-315, for basal cell carcinoma. Verrica will present Phase 2 study data, highlighting an observed abscopal-like effect in non-treated lesions, at the 2026 Society for Investigative Dermatology (SID) Annual Meeting from May 13-16, 2026. Preparations for a Phase 3 study of VP-315 are also underway.
• Verrica reported total revenue of $5.0 million for Q1 2026, including $4.3 million in U.S. YCANTH net product revenue and $0.7 million in license and collaboration revenue, primarily from the Japan launch. The company recorded a net loss of $9.7 million, or $0.45 per share, for the quarter, consistent with the prior year, while R&D expenses increased due to the common warts Phase 3 program.

Addressing Unmet Needs in Molluscum Contagiosum Treatment

Current treatment approaches for molluscum contagiosum face significant challenges that limit therapeutic success and patient outcomes. These limitations span across treatment modalities, patient factors, and evidence gaps that collectively highlight the need for improved therapeutic strategies.

• High treatment failure rates affect standard interventions, with curettage showing failure rates of 66% at week 4 and 45% at week 8, while recurrence rates reach 49.2% for curettage and 35% for electrodessication

• Patient-specific risk factors significantly impact treatment success, including number of lesions at baseline (P < 0.001), number of involved anatomical sites (P < 0.001), and presence of concomitant atopic dermatitis (P = 0.038 at week 4 and P < 0.001 at week 8)

• Poor medication adherence severely limits the utility of topical treatments in clinical practice, with lower adherence rates observed for topical versus procedural treatments due to delayed effects, long treatment duration, and uncertain perceived benefits

• Local tolerability issues compromise treatment completion, as cidofovir gel causes significant local inflammation and intolerance, with some patients discontinuing therapy due to adverse reactions

• Limited efficacy in immunocompromised populations, particularly in HIV-infected patients where only partial responses are observed in severely immunodepressed individuals, despite topical cidofovir being indicated for extensive lesions

• Absence of treatment consensus due to lack of a gold standard therapy and insufficient clinical evidence, requiring larger well-designed trials that account for adherence before evidence-based recommendations can be established

• Anatomical location challenges, particularly with eyelid molluscum contagiosum presenting both diagnostic and therapeutic difficulties due to proximity to sensitive structures

• Uncertain long-term efficacy of newer agents like VP-102 and SB206, which show promise in clinical trials but have unclear ability to address fundamental adherence challenges in real-world practice

YCANTH's Phase 3 Program for Common Warts: Design and Potential

YCANTH (VP-102) is being developed for external genital warts caused by various subtypes of the human papilloma virus, which spread through direct skin-to-skin contact and affect approximately 1% of the US population. VP-102 is formulated as a drug-device combination product containing cantharidin 0.7% w/v in a single-use shelf-stable applicator, designed to deliver precise dosing for topical treatment.

The clinical development program employed a randomized, double-blind, vehicle-controlled Phase II trial design conducted in two sequential parts. Part A focused on dose-finding to identify optimal treatment regimens, while Part B evaluated safety and efficacy following completion of Part A. Based on Part A results, 6-hour and 24-hour VP-102 regimens under occlusion were selected for evaluation in Part B, representing the intervention model that balances therapeutic exposure with practical clinical application.

Pooled efficacy results demonstrated that 36.7% and 33.3% of participants achieved complete clearance of all treatable external genital warts with 6-hour and 24-hour VP-102 regimens respectively, compared to 4.2% (p < 0.0048) and 0% (p < 0.0075) with vehicle control. The favorable risk-benefit profile observed with both exposure durations has justified advancement to a larger vehicle-controlled Phase III program in external genital warts, with the completed Phase II study (NCT03981822) serving as the foundation for this expanded clinical development strategy.

Shaping the Molluscum Contagiosum Treatment Landscape

The molluscum contagiosum treatment landscape has undergone significant transformation over the past five years, marked by the introduction of two FDA-approved topical therapies that represent the first standardized pharmaceutical interventions for this condition. Zelsuvmi (berdazimer gel 10.3%) received FDA approval in 2026, featuring a nitric oxide-releasing agent that provides dual-action efficacy through viral replication inhibition and immunomodulatory effects. The pivotal B-SIMPLE4 trial demonstrated superior lesion clearance rates compared to vehicle treatments, with notable efficacy even in patients with atopic dermatitis and a favorable safety profile characterized by mild localized skin reactions. Concurrently, YCANTH (VP-102, cantharidin 0.7%) gained approval for patients aged ≥2 years and adults, with phase-3 trials (CAMP-1 and CAMP-2) showing complete clearance rates of 46-54% versus 13-18% with vehicle at day 84, administered once every 21 days for up to four treatments.

Comparative efficacy data from a comprehensive 2023 network meta-analysis of 25 randomized controlled trials involving 2,123 participants has provided critical guidance for treatment selection. The analysis revealed that ingenol mebutate demonstrated the highest odds ratio for complete clearance (OR 117.42), followed by cryotherapy (OR 16.81), podophyllotoxin (OR 10.24), and potassium hydroxide (OR 10.02) compared to placebo. However, safety concerns regarding ingenol mebutate have subsequently emerged, while traditional therapies like cryotherapy and keratolytic agents remain principal treatment options. Recent procedural treatment comparisons have shown that curettage offers superior outcomes over electrodessication, with significantly fewer remnants (42.9% vs 70%), greater aesthetic satisfaction, and faster recovery times in pediatric patients.

Treatment adherence challenges have emerged as a critical limiting factor in therapeutic efficacy, particularly for home-administered topical medications. Studies conducted between 2000-2023 revealed consistently poor adherence to individual topical treatments due to delayed effects, prolonged treatment duration, and uncertain perceived benefits. This adherence gap has highlighted the potential advantage of in-office treatments like cantharidin, which may overcome compliance issues while enhancing therapeutic outcomes. Clinical practice pattern analysis from 2000-2016 showed persistent disparities in treatment approaches, with dermatologists favoring active interventions (terpenoids 20%, imiquimod 12%, curettage 10%) while pediatricians predominantly supported expectant management, reflecting the ongoing clinical debate between intervention versus observation for this self-limiting condition.

Capitalizing on First-in-Class Success and Strategic Pipeline Expansion

This quarter's financial results from Verrica Pharmaceuticals paint a compelling picture of a company successfully capitalizing on a significant unmet medical need while strategically building out its pipeline. The robust growth of YCANTH (VP-102) for molluscum contagiosum (MC) is particularly noteworthy. As the first and only FDA-approved treatment for MC, YCANTH has rapidly established itself in a market previously characterized by varied, often painful, and unapproved therapies. The impressive 51.3% year-over-year increase in dispensed units and strong revenue figures underscore the substantial demand for a standardized, clinically validated solution for this common pediatric skin infection. This success is further amplified by its recent commercial launch in Japan, demonstrating effective global market penetration through strategic partnerships.

However, the path forward involves navigating both opportunities and potential challenges. While YCANTH's dominance in MC is clear, the company's expansion of VP-102 into common warts faces a more crowded landscape. Existing literature suggests that cantharidin, while efficacious, may not always offer superior outcomes compared to other conventional wart treatments. This implies that Verrica will need to clearly articulate the differentiated value proposition of its proprietary formulation and application method to gain significant traction in this indication. Furthermore, the inherent nature of cantharidin as a vesicant means that application site reactions like blistering and pain are expected. While generally mild to moderate, managing these adverse events and ensuring high patient and caregiver satisfaction, particularly in a pediatric population, will be crucial for sustained adoption and adherence.

Beyond the cantharidin platform, Verrica's advancement of VP-315 for basal cell carcinoma introduces an exciting diversification. This oncolytic peptide, with its novel immunotherapeutic mechanism, represents a promising avenue in oncology, particularly given its demonstrated ability to induce complete responses and activate systemic anticancer immunity. The upcoming Phase 2 data presentation for VP-315 will be a key event, offering insights into its potential to address another area of high unmet need and positioning Verrica as an innovator beyond dermatology. This multi-pronged strategy, balancing a strong commercial foundation with a diversified, high-potential pipeline, suggests a thoughtful approach to long-term growth and value creation in specialized therapeutic areas.